Cell Surface Sialoglycan Engineering Through Exogenous mRNA

All human cells display a dense matrix of structurally diverse glycans that often terminate in monosaccharides belonging to the sialic acid family of sugars. While these sialoglycans are now recognized as critical regulators of human immunity, there is a lack of technologies that provide precise, transient control over their biosynthesis and presentation on a live cell surface. Here, we addressed this unmet need by developing an mRNA-based platform for delivery of transcripts coding for the enzymes that assemble sialoglycans - sialyltransferases - to human cells. We demonstrated that mRNA coding for the 2-6-specific sialyltransferase ST6Gal1 produced active, Golgi-resident enzyme that potentiated levels of 2-6-sialoglycans on the surface of human cell lines. Increased presentation of these sialoglycans was transient and tracked with the degradation kinetics of the delivered mRNA. Importantly, this approach minimally perturbed other classes of glycans and did not broadly alter physiological transcriptional networks beyond those involved in cellular responses to exogenous RNA. Similar on-target effects were observed for the O-linked 2-6-specific sialyltransferase ST6GalNAc4; however, the effects from mRNA coding for the 2-3-specific sialyltransferases ST3Gal1 and ST3Gal4 were more complex. Taken together, this mRNA platform provides a framework for cellular sialoglycoengineering endeavours, where precise and reversible control over glycocalyx composition is desired.